Celgene moves to dismiss United HealthCare’s antitrust claims over Revlimid, Thalomid
MLex Summary: Celgene told a US federal judge that United HealthCare’s antitrust claims over Thalomid and Revlimid are untimely and fail to plead any plausible unlawful conduct. It said that Celgene’s...To view the full article, register now.
Already a subscriber? Click here to view full article